Literature DB >> 17562804

Pharmacokinetics, safety, and hydrolysis of oral pyrroloquinazolinediamines administered in single and multiple doses in rats.

Qigui Li1, Michael P Kozar, Todd W Shearer, Lisa H Xie, Ai J Lin, Kirsten S Smith, Yuanzheng Si, Lalaine Anova, Jing Zhang, Wilbur K Milhous, Donald R Skillman.   

Abstract

Pyrroloquinazolinediamine (PQD) derivatives such as tetra-acetamide PQD (PQD-A4) and bis-ethylcarbamyl PQD (PQD-BE) were much safer (with therapeutic indices of 80 and 32, respectively) than their parent compound, PQD (therapeutic index, 10). Further evaluation of PQD-A4 and PQD-BE in single and multiple pharmacokinetic (PK) studies as well as corresponding toxicity studies was conducted with rats. PQD-A4 could be converted to two intermediate metabolites (monoacetamide PQD and bisacetamide PQD) first and then to the final metabolite, PQD, while PQD-BE was directly hydrolyzed to PQD without precursor and intermediate metabolites. Maximum tolerant doses showed that PQD-A4 and PQD-BE have only 1/12 and 1/6, respectively, of the toxicity of PQD after a single oral dose. Compared to the area under the concentration-time curve for PQD alone (2,965 ng.h/ml), values measured in animals treated with PQD-A4 and PQD-BE were one-third (1,047 ng.h/ml) and one-half (1,381 ng.h/ml) as high, respectively, after an equimolar dosage, suggesting that PQD was the only agent to induce the toxicity. Similar results were also shown in multiple treatments; PQD-A4 and PQD-BE generated two-fifths and three-fifths, respectively, of PQD concentrations, with 8.8-fold and 3.8-fold safety margins, respectively, over the parent drug. PK data indicated that the bioavailability of oral PQD-A4 was greatly limited at high dose levels, that PQD-A4 was slowly converted to PQD via a sequential three-step process of conversion, and that PQD-A4 was significantly less toxic than the one-step hydrolysis drug, PQD-BE. It was concluded that the slow and smaller release of PQD was the main reason for the reduction in toxicity and that the active intermediate metabolites can still maintain antimalarial potency. Therefore, the candidate with multiple-step hydrolysis of PQD could be developed as a safer potential agent for malaria treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562804      PMCID: PMC1932520          DOI: 10.1128/AAC.00932-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  The relationship between premorbid body weight, weight loss, and weight at referral in adolescent patients with anorexia nervosa.

Authors:  H Coners; H Remschmidt; J Hebebrand
Journal:  Int J Eat Disord       Date:  1999-09       Impact factor: 4.861

2.  Quantitative definition of toxicity: a mathematical description of life and death with dose and time as variables.

Authors:  K K Rozman
Journal:  Med Hypotheses       Date:  1998-08       Impact factor: 1.538

3.  Folate antagonists. 9. 2,4-Diamino-6-((aralkyl)alkylamino)quinazolines, a potent class of antimetabolites with prodigious antimalarial effects.

Authors:  E F Elslager; O D Bird; J Clarke; S C Perricone; D F Worth
Journal:  J Med Chem       Date:  1972-11       Impact factor: 7.446

4.  Absorption, metabolism, and other factors that influence drug exposure in toxicology studies.

Authors:  P R Mayer
Journal:  Toxicol Pathol       Date:  1995 Mar-Apr       Impact factor: 1.902

5.  Folate antagonists. 2. 2,4-Diamino-6-((aralkyl and (heterocyclic)methyl)amino)quinazolines, a novel class of antimetabolites of interest in drug-resistant malaria and Chagas' disease.

Authors:  J Davoll; A M Johnson; H J Davies; O D Bird; J Clarke; E F Elslager
Journal:  J Med Chem       Date:  1972-08       Impact factor: 7.446

6.  Plasmodium berghei: production and quantitation of hepatic stages derived from irradiated sporozoites in rats and mice.

Authors:  L F Scheller; K C Stump; A F Azad
Journal:  J Parasitol       Date:  1995-02       Impact factor: 1.276

7.  An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.

Authors:  S G Chaney; G R Gibbons; S D Wyrick; P Podhasky
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

8.  Relationship of body energy status to inflammation-induced anorexia and weight loss.

Authors:  T A Lennie
Journal:  Physiol Behav       Date:  1998-06-15

9.  Effects of initial body weight on anorexia and tolerance to fenfluramine in rats.

Authors:  J Carlton; N Rowland
Journal:  Pharmacol Biochem Behav       Date:  1985-10       Impact factor: 3.533

10.  Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection.

Authors:  P A Burghaus; B T Wellde; T Hall; R L Richards; A F Egan; E M Riley; W R Ballou; A A Holder
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

View more
  2 in total

1.  The chemistry and pharmacology of privileged pyrroloquinazolines.

Authors:  Bo Chao; Bingbing X Li; Xiangshu Xiao
Journal:  Medchemcomm       Date:  2015-04-01       Impact factor: 3.597

2.  Discovery of a Potent Anti-tumor Agent through Regioselective Mono-N-acylation of 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine.

Authors:  Jingjin Chen; Alina Kassenbrock; Bingbing X Li; Xiangshu Xiao
Journal:  Medchemcomm       Date:  2013-09-01       Impact factor: 3.597

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.